# Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

> **NCT01235936** · PHASE2 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- Anemia
- Kidney Disease

## Interventions

- **DRUG:** AKB-6548

## Key facts

- **NCT ID:** NCT01235936
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-21
- **Primary completion:** 2011-04-13
- **Final completion:** 2011-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235936, "Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01235936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*